Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

JNJJanssen Research & Development, LLCFinished

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 4 insiders sold shares within a month

    Since Aug 17, 2026 · was worth 5, fading over time

    +2
Worry score2

Score over time

Stage
Phase 2
Patients
36 (final count)
Started
Dec 6, 2022
Main results expected
Dec 6, 2023
Fully finished
Sep 26, 2024
Results posted
Jan 13, 2025

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B

    Measured over: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm

    Measured over: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

  • Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B

    Measured over: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  • Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm

    Measured over: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

  • Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B

    Measured over: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  • Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm

    Measured over: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT05564052 · record last updated 2025-10-07 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05564052) ↗

Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B

Measured over: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)

  • Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Monotherapy Arm

    Measured over: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)

  • Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Arms A1, A2, A3 and B

    Measured over: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)

  • Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Monotherapy Arm

    Measured over: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)